Cortisol in cardio-kidney-metabolic disease.
The epidemiology and mechanisms linking cortisol excess to CKM dysfunction are summarized, and the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk is highlighted.